A leading pharmaceutical company leveraged NorstellaLinQ’s integrated real-world data and analytic expertise to better understand competitive market shifts, uncover new patient opportunities, and inform strategic decisions that supported sustained commercial success. The company:
A global pharma company whose early-stage breast cancer drug had a longtime stronghold on the marketplace saw volume for its drug decrease when its competitor launched a similar treatment. The client’s drug was still being prescribed at many healthcare organizations, but was ceding share to its competitor’s drug, especially at major academic centers. Furthermore, the competitor’s drug had a specific indication that the client’s drug lacked, presenting a strategic challenge. To avoid losing ground in the market, the client needed both insights and consulting expertise to understand where its drug was falling short.
The client used NorstellaLinQ, a fully integrated real-world data ecosystem with claims, labs, and EHR data, to identify new-to-brand biomarker-eligible patients. With NorstellaLinQ, Norstella projected how many monthly scripts the client’s drug would capture in its segment over the year, highlighting opportunities to quantify and shift the drug’s trajectory in the evolving marketplace.
Leveraging the breadth and depth of unstructured data gave the client patient-specific insights that showed the stage and progression of the disease. By combining data curation, real-world data, and Norstella’s analytic consulting expertise, the client determined how insights around understanding disease progression and HCP behavior could be used to enhance commercialization efforts and therapy uptake.
The combination of data and consulting helped the client quantify market shifts to uncover strategic opportunities and guide commercial planning. NorstellaLinQ’s integrated set of claims, labs, and EHR data helped uncover new insights about the treatment, and partnering with Norstella’s clinical and medical science teams helped the client achieve its overall commercialization goals.
This integrated real-world data approach delivered actionable insights to support the breast cancer drug’s strategic positioning, market evolution, and long-term growth planning. NorstellaLinQ’s unstructured EHR capabilities brought critical color to the dynamics of the competitive landscape, helping the client rise above competitors by capturing the “why” behind treatment decisions.
Get Started
Frequently asked questions
Integrated real-world data combines claims, laboratory and EHR data to help pharmaceutical companies identify biomarker-eligible patients, monitor market dynamics and uncover opportunities to strengthen commercialization strategies.
By analyzing prescribing patterns, disease progression and patient movement across therapies, integrated real-world data provides actionable insights into why market share changes occur and where new growth opportunities exist.
Evaluating healthcare provider prescribing behavior helps manufacturers identify factors influencing treatment decisions, refine commercial strategies and better engage providers to support appropriate therapy adoption.
After a competing breast cancer therapy entered the market, the manufacturer needed to understand declining market share, identify biomarker-eligible patients and uncover the clinical and competitive factors influencing prescribing decisions. Norstella combined integrated real-world data with analytic consulting expertise to provide those insights.
Norstella helped the manufacturer quantify market shifts, identify strategic growth opportunities, uncover the drivers behind treatment decisions and support long-term commercial planning through integrated real-world data and analytics.
